Just like Wegovy and Ozempic, Zepbound and Mounjaro are two brand names for the same medication— tirzepatide. This guide explains the differences between these two products and helps you understand which one might be right for you.
Official Assessment
Zepbound and Mounjaro contain identical medication (tirzepatide) made by Eli Lilly. Mounjaro is approved for type 2 diabetes, while Zepbound is approved for chronic weight management. The dosing is the same—the only real differences are the FDA-approved uses and insurance coverage.
Comparison at a Glance
| Feature | Mounjaro | Zepbound |
|---|---|---|
| Active Ingredient | Tirzepatide | Tirzepatide |
| FDA Approval | Type 2 diabetes (2022) | Chronic weight management (2023) |
| Dose Range | 2.5 mg to 15 mg | 2.5 mg to 15 mg |
| Available Doses | 2.5, 5, 7.5, 10, 12.5, 15 mg | 2.5, 5, 7.5, 10, 12.5, 15 mg |
| List Price | ~$1,060/month | ~$1,060/month |
Why Two Products?
Eli Lilly followed the same strategy as Novo Nordisk with semaglutide:
- Mounjaro launched first — Approved May 2022 for type 2 diabetes
- Weight loss trials followed — The SURMOUNT studies showed exceptional results
- Zepbound launched — Approved November 2023 specifically for obesity
- Different packaging — But identical medication inside
Tirzepatide's Dual Action
What makes tirzepatide unique is its dual mechanism:
GLP-1 Receptor Agonist
Like semaglutide, it activates GLP-1 receptors to reduce appetite and slow gastric emptying.
GIP Receptor Agonist
Also activates GIP receptors, which may enhance insulin sensitivity and improve fat metabolism.
Insurance and Coverage
Mounjaro Coverage
Better coverage if you have type 2 diabetes. Many insurance plans cover it for this indication. Off-label use for weight loss typically isn't covered.
Zepbound Coverage
Limited coverage for weight loss indications. Some commercial plans are starting to cover it, but Medicare and most Medicaid programs don't cover weight loss medications.
Clinical Results
Both products produce the same impressive results from the SURMOUNT trials:
- Average weight loss: 20-26% of body weight at highest doses
- Metabolic improvements: Significant A1C reduction, improved lipids
- Blood pressure: Average 4-6 mmHg reduction
- 72-week results: Sustained weight loss with continued use
Official Summary
Zepbound and Mounjaro are the same medication. Your choice will likely depend on whether you have type 2 diabetes (favoring Mounjaro for insurance purposes) or are primarily seeking weight loss (Zepbound has the specific approval). Both offer the most powerful weight loss results currently available in a medication.